InvestorsHub Logo
Followers 3
Posts 276
Boards Moderated 0
Alias Born 12/21/2022

Re: Gogh9 post# 3276

Wednesday, 07/26/2023 11:46:15 AM

Wednesday, July 26, 2023 11:46:15 AM

Post# of 3283
Yes, maybe not worth it. Wonder why they are still presenting data. Here is a title of oral presentation at WCLC 2023 meeting in September: "Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies". Authors: X. Le, A. Prelaj, C. Baik, N. Tchekmedyian, S. Leu, G. Bhat, J.V. Heymach, R. Cornelissen.